Alzheimer's disease is a space that has seen a lot of failure from pharmaceutical companies, including Eli Lilly (LLY +0.54%), whose drug solanezumab has failed two phase 3 trials. But now, the company is going back and giving it one more shot. In this video, Motley Fool health care analyst David Williamson tells us why, in this particular space, achieving any results at all may be a huge financial win, and whether Eli Lilly should in fact be pushing for this drug in a limited capacity or if it's chasing a rabbit down a hole that may ultimately elude it.
Is Eli Lilly on a Fruitless Quest?
By Dave Williamson and Brenton Flynn – Dec 13, 2012 at 7:00PM
NYSE: LLY
Eli Lilly
Market Cap
$781B
Today's Change
(0.54%) $4.41
Current Price
$825.45
Price as of October 24, 2025 at 4:00 PM ET
This company's Alzheimer's disease drug may never be approved. Should Eli Lilly keep pushing?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid